Oncology
The findings show that bacterial metabolites can sensitize cancer cells to treatment with immunotherapy by boosting the expression of HLA class I molecules.
Understanding how antibiotics influence the microbiota’s impacts on immunotherapy may inform strategies to identify cancer patients that are more likely to respond to cancer treatment.
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
The findings of a recent study suggest that targeting the interactions between MAdCAM-1 and specific receptors on the surface of immune cells may help to improve immunotherapy outcomes.
Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, gives an overview of preclinical and clinical results for MaaT013 and MaaT033.
By providing insights into how the gut microbiota influences cancer susceptibility, the findings may help to develop new therapies or dietary interventions.
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Microbiomepost discussed with Lorella Tripodi, University Federico II of Naples, about the research she is working with her colleagues.
Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.
The findings of a recent study suggest that tilimycin-producing bacteria can cause genetic mutations in the colon and increase a person’s susceptibility to disease.
